Price Alert

Metsera Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD

51.90

0.20 (0.39%)

At close: Oct 03, 2025, 3:59 PM

51.76

-0.27%

After-hours: Oct 03, 2025, 07:18 PM EDT

0.39% (1D)

Bid	51.49
Market Cap	5.45B
Revenue (ttm)	n/a
Net Income (ttm)	-307.82M
EPS (ttm)	-2.92
PE Ratio (ttm)	-17.77
Forward PE	-14.2
Analyst	Buy
Dividends	n/a

Ask	52.1
Volume	1,045,874
Avg. Volume (20D)	2,013,874
Open	51.66
Previous Close	51.70
Day's Range	51.62 - 52.06
52-Week Range	12.30 - 54.47
Beta	1.63
Ex-Dividend Date	n/a

About MTSR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MTSR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MTSR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 week ago

+60.8%

Metsera shares are trading higher on reports that ... Unlock content with Pro Subscription

2 months ago

-5.73%

Metsera shares are trading lower after the company reported worse-than-expected Q2 EPS results.

News

5 days ago · cnbc.com

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

4 days ago · barrons.com

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.

6 days ago · reuters.com

Metsera's obesity drug shows promising weight loss in mid-stage trials

Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies.

1 week ago · zacks.com

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?

Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).

1 week ago · businesswire.com

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...

1 week ago · proactiveinvestors.co.uk

Pfizer's Metsera buy raises competitive heat for Novo Nordisk

UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towa...

1 week ago · fastcompany.com

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...

1 week ago · youtube.com

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.

1 week ago · schaeffersresearch.com

Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.

1 week ago · proactiveinvestors.com

Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline

Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. ...

Load More News